Researcher's Presentation Supports the Use of Longport's Technology

  
    
  
  
    
      Longport, Inc. (OTC PK: LPTI), a medical technology specialist in 
      high-frequency, high-resolution ultrasound imaging, today announced a 
      March 7 presentation at the New Jersey Hospital Association Pressure 
      Ulcer Collaborative by Karen Zulkowski, DNS, RN, CWS, supporting the use 
      of Longport’s EPISCAN.
    
    
      Dr. Zulkowski, the principal investigator exploring the use of Longport’s 
      EPISCAN I-200 for improved clinical detection of pressure ulcer risk and 
      development, gave an overview of study progress and presented a case 
      study. Key points outlined by Dr. Zulkowski included her findings that 
      more than 90% of new admissions to the facilities had ultrasound changes 
      consistent with tissue injury, most in the absence of overt skin 
      changes. Furthermore, she commented, “care 
      planning and intervention on the basis of ultrasound findings may help 
      to differentiate avoidable versus unavoidable (pressure ulcers) pursuant 
      to the regulatory oversight process.” Of 
      particular interest to Dr. Zulkowski was how the use of the EPISCAN 
      I-200 made an impact on nursing care when used as a teaching tool; “this 
      is an excellent teaching tool showing the staff that there is actually 
      something going on under the skin even though you can’t 
      see it on the surface.”
    
    
      Dr. Zulkowski concluded her presentation by saying that “early 
      recognition of deep tissue changes is an important step in providing 
      pressure ulcer prevention. Ultrasound technology is now able to help 
      identify these tissue changes before they are observable on the skin 
      surface. Integration of ultrasound into clinical practice can help 
      facilitate earlier care planning for pressure ulcer prevention.”
    
    
      Dr. Zulkowski is a professor of nursing at Montana State 
      University-Bozeman and is an alumnus of the National Pressure Ulcer 
      Advisory Panel (NPUAP).
    
    
      Further details on this presentation and other clinical study papers can 
      be viewed in the News section of Longport’s 
      web site: http://www.longportinc.com/about/news.html.
    
    
      “This presentation in concert with clinical 
      study results further validates the use of our technology for clinical 
      acceptance and clinical use,” said Connie 
      Phillips-Jones, RN, MSN, Longport’s Director 
      of Clinical Support.
    
    
      About Longport, Inc.
    
    
      Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology 
      company that specializes in high-resolution ultrasound imaging. After 
      several years and a multimillion dollar investment in the technology, 
      Longport has secured patents, copyrights and FDA permission to market. 
      The Company’s technology has been used to 
      engineer a unique high-resolution ultrasound imaging system. For further 
      information, please contact Longport, Inc. at 1-800-289-6863 or visit 
      our website at www.longportinc.com.
    
    
      Forward-looking Information and the Private Securities Litigation 
      Reform Act of 1995
    
    
      Certain statements in this press release, including statements 
      concerning product development milestones and anticipated events, are “forward-looking 
      statements” within the Private Litigation 
      Reform Act of 1995. Forward Looking Statements are based on the 
      opinions and estimates of management at the time the statements are made 
      and are subject to certain risks and uncertainties that could cause 
      actual results to differ materially from those anticipated in the 
      forward-looking statements. The words “believe,” 
      “expect,” “intend,” 
      “anticipate,” 
      variations of such words, and similar expressions identify 
      forward-looking statements, but their absence does not mean that the 
      statement is not forward-looking. These statements are not 
      guarantees of future performance and are subject to certain risks, 
      uncertainties and assumptions that are difficult to predict. Factors 
      that could affect Longport’s actual results 
      include, among others, uncertainties as to the Company’s 
      ability to manage potential problems, delays or anticipated expenses, 
      including problems, delays or expenses involving manufacturing. Readers 
      are cautioned not to place undue reliance upon these forward-looking 
      statements that speak only to the date of this release. Reference 
      is made to Longport’s 2004 annual report on 
      Form 10-K filed with the Securities and Exchange Commission for a more 
      definitive description of such factors. Longport, Inc. undertakes 
      no obligation to update publicly any forward-looking statements to 
      reflect new information, events or circumstances after the date of this 
      release or to reflect the occurrence of unanticipated events.